Apheresis Market Size by Product (Device (Centrifugation, Membrane Separation) Disposable), Procedure (Donor, Therapeutic), Application (Plasmapheresis, Plateletpheresis), Technology, End-User (Hospital, Blood Collection Center), Region - Global Forecast to 2029
The global apheresis market is projected to reach USD 3.9 billion by 2029 from USD 2.6 billion in 2024, at a CAGR of 8.8% from 2024 to 2029. The growth of the market is driven by a rising incidence of trauma and injury cases, upsurging number of complex surgical procedure. The market also benefits from rise in investments from government bodies and key players and the surge in use of apheresis procedure for leukaemia and paediatric patients.
However, significant expenses associated with apheresis devices and therapeutic procedures, along with the option of installing apheresis devices via rental agreements, are impacting the industry. Moreover, decline in apheresis-based blood donations due to insufficient awareness among potential donors is a major factor restraining the market growth.
“Therapeutic apheresis disposables segment to witness the highest growth during the forecast period.”
Based on procedure, the segment is divided into automated blood collection and therapeutic apheresis. The therapeutic apheresis is further divided into therapeutic apheresis disposables and therapeutic apheresis devices. The therapeutic apheresis disposables witness the highest growth in the apheresis market during the forecast period, attributing to rise in awareness about apheresis procedures, particularly for therapeutic purposes. This increased awareness has led to a growing acceptance of apheresis as an effective treatment option among healthcare providers and patients alike. Moreover, there is a significant increase in research activities focusing on apheresis procedures for therapeutic applications. This ongoing research is uncovering new insights into the efficacy and versatility of apheresis in treating various medical conditions, ranging from autoimmune disorders to hematologic malignancies. Thus, healthcare professionals are increasingly incorporating these procedures into their treatment protocols. As a result, the demand for therapeutic apheresis procedures is expected to surge in the coming years.
“Continuous flow centrifugation segment accounted for the largest share in the apheresis market during the forecast period.”
Based on technology, the apheresis market is segmented into centrifugation, and membrane separation. The centrifugation segment is further divided into continuous flow centrifugation and intermittent flow centrifugation. Among these, the continuous flow centrifugation segment accounted for largest share in the apheresis market in 2023. As continuous flow centrifugation technology is highly preferred in both blood collection and therapeutic apheresis procedures due to its efficiency and effectiveness. This technology allows for a smoother and more consistent separation process, leading to higher yields of desired blood components. As a result, healthcare facilities and blood collection centers Favor continuous flow centrifugation systems to streamline their operations and improve overall productivity. Moreover, continuous flow centrifugation technology offers several distinct advantages, such as its ability to operate with a small extracorporeal volume (ECV), minimizing the patient's exposure to extracorporeal circulation. Additionally, this technology is associated with shorter procedural times and requires relatively low volumes of anticoagulants, which enhances patient safety and comfort. These advantages make continuous flow centrifugation a preferred choice among healthcare providers, thus increasing the market growth during forecasting period.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the apheresis market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period, attributing to expansion of healthcare infrastructure and blood banking facilities. This is due to increasing support from governments across the region for the development of healthcare infrastructure. These countries are growing economically thus, governments are allocating substantial resources towards enhancing healthcare services, including the establishment of modern medical facilities and the adoption of advanced medical technologies like apheresis devices. Moreover, increasing awareness of the importance of safe blood transfusions and the need for advanced blood collection and processing techniques, governments and healthcare authorities are incentivizing the expansion and modernization of blood banking facilities. Thus, increasing the government-licensed and accredited blood banks, leading to rise in the growth of apheresis market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This report studies the apheresis market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
However, significant expenses associated with apheresis devices and therapeutic procedures, along with the option of installing apheresis devices via rental agreements, are impacting the industry. Moreover, decline in apheresis-based blood donations due to insufficient awareness among potential donors is a major factor restraining the market growth.
“Therapeutic apheresis disposables segment to witness the highest growth during the forecast period.”
Based on procedure, the segment is divided into automated blood collection and therapeutic apheresis. The therapeutic apheresis is further divided into therapeutic apheresis disposables and therapeutic apheresis devices. The therapeutic apheresis disposables witness the highest growth in the apheresis market during the forecast period, attributing to rise in awareness about apheresis procedures, particularly for therapeutic purposes. This increased awareness has led to a growing acceptance of apheresis as an effective treatment option among healthcare providers and patients alike. Moreover, there is a significant increase in research activities focusing on apheresis procedures for therapeutic applications. This ongoing research is uncovering new insights into the efficacy and versatility of apheresis in treating various medical conditions, ranging from autoimmune disorders to hematologic malignancies. Thus, healthcare professionals are increasingly incorporating these procedures into their treatment protocols. As a result, the demand for therapeutic apheresis procedures is expected to surge in the coming years.
“Continuous flow centrifugation segment accounted for the largest share in the apheresis market during the forecast period.”
Based on technology, the apheresis market is segmented into centrifugation, and membrane separation. The centrifugation segment is further divided into continuous flow centrifugation and intermittent flow centrifugation. Among these, the continuous flow centrifugation segment accounted for largest share in the apheresis market in 2023. As continuous flow centrifugation technology is highly preferred in both blood collection and therapeutic apheresis procedures due to its efficiency and effectiveness. This technology allows for a smoother and more consistent separation process, leading to higher yields of desired blood components. As a result, healthcare facilities and blood collection centers Favor continuous flow centrifugation systems to streamline their operations and improve overall productivity. Moreover, continuous flow centrifugation technology offers several distinct advantages, such as its ability to operate with a small extracorporeal volume (ECV), minimizing the patient's exposure to extracorporeal circulation. Additionally, this technology is associated with shorter procedural times and requires relatively low volumes of anticoagulants, which enhances patient safety and comfort. These advantages make continuous flow centrifugation a preferred choice among healthcare providers, thus increasing the market growth during forecasting period.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the apheresis market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period, attributing to expansion of healthcare infrastructure and blood banking facilities. This is due to increasing support from governments across the region for the development of healthcare infrastructure. These countries are growing economically thus, governments are allocating substantial resources towards enhancing healthcare services, including the establishment of modern medical facilities and the adoption of advanced medical technologies like apheresis devices. Moreover, increasing awareness of the importance of safe blood transfusions and the need for advanced blood collection and processing techniques, governments and healthcare authorities are incentivizing the expansion and modernization of blood banking facilities. Thus, increasing the government-licensed and accredited blood banks, leading to rise in the growth of apheresis market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
- By Designation: C-level (30%), Director-level (20%), and Others (50%)
- By Region: North America (35%), Europe (24%), Asia Pacific (25%), Latin America and Middle East Africa (16%)
- Terumo BCT, Inc. (Japan)
- Fresenius SE & Co. KGaA (Germany)
- Haemonetics Corporation (US)
- Baxter International Inc. (US)
- Asahi Kasei Medical Co., Ltd. (Japan)
- B. Braun Melsungen AG (Germany)
- Cerus Corporation (US)
- Kaneka Corporation (Japan)
- SB-Kawasumi Laboratories, Inc (Japan)
- Nikkiso Co., Ltd (Japan)
- Macopharma SA (France)
- Miltenyi Biotec (Germany)
- Otsuka Holdings Co., Ltd. (Japan)
- Medica S.p.A. (Italy)
- Mallinckrodt plc (Ireland)
- Becton, Dickinson and Company (US)
- LMB Technologie GmbH (Germany)
- Bioelettronica S.r.l. (Italy)
- Infomed SA (Switzerland)
- Cytosorbents Corporation (US)
- Medicap clinic GmbH (Germany)
- Haier Biomedical (China)
- Beijing ZKSK Technology Co., Ltd. (China)
- Guangzhou Daji Medical Science and Technology Co. Ltd (China)
- PuriBlood Medical (Taiwan)
This report studies the apheresis market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (increasing prevalence of trauma and injury cases, rise in demand for source plasma from biopharmaceutical companies, upsurging number of complex surgical procedures, and favourable reimbursement for apheresis procedures) ,restraints (High cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through rental model, Fewer blood donations using apheresis due to lack of awareness, Stringent donor recruitment criteria), challenges (recruitment of voluntary non-remunerated donors, and safety of blood transfusion in developing countries), opportunities (apheresis for leukaemia and paediatric patients, and emerging economies with increasing investments from government authorities and key players) contributing the growth of the apheresis market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the apheresis market.
- Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
- Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the apheresis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global apheresis market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 PRODUCT DEFINITION
1.2.2 TECHNOLOGY DEFINITION
1.2.3 APPLICATION DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
TABLE 1 CURRENCY CONVERSION RATES
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT
FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029): IMPACT LEVEL
FIGURE 8 CAGR PROJECTIONS
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 APHERESIS DISPOSABLES TO BE LARGEST SEGMENT DURING FORECAST PERIOD
FIGURE 11 CENTRIFUGAL APHERESIS DEVICES SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD
FIGURE 12 AUTOMATED BLOOD COLLECTION TO BE LEADING SEGMENT DURING FORECAST PERIOD
FIGURE 13 THERAPEUTIC APHERESIS DISPOSABLES TO HOLD DOMINANT SHARE BY 2029
FIGURE 14 NEUROLOGICAL DISORDERS TO BE LEADING SEGMENT DURING FORECAST PERIOD
FIGURE 15 CENTRIFUGATION TECHNOLOGY TO DOMINATE APHERESIS MARKET DURING FORECAST PERIOD
FIGURE 16 CONTINUOUS FLOW CENTRIFUGATION TO BE MAJOR SEGMENT DURING FORECAST PERIOD
FIGURE 17 PLASMAPHERESIS SEGMENT TO HOLD LARGEST SHARE BY 2029
FIGURE 18 COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS – MAJOR SEGMENT BY 2029
FIGURE 19 ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR APHERESIS
4 PREMIUM INSIGHTS
4.1 APHERESIS MARKET OVERVIEW
FIGURE 20 RISING PREVALENCE OF DISEASES AND GROWING NUMBER OF TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION & COUNTRY
FIGURE 21 PLASMAPHERESIS AND GERMANY ACCOUNTED FOR LARGEST SHARE OF EUROPEAN APHERESIS MARKET IN 2023
4.3 REGIONAL SNAPSHOT OF APHERESIS MARKET (2023)
FIGURE 22 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
4.4 REGIONAL MIX: APHERESIS MARKET, 2024–2029 (USD MILLION)
FIGURE 23 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)
FIGURE 24 DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 25 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases and trauma/injury cases
FIGURE 26 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS)
5.2.1.2 Increasing demand for source plasma from biopharmaceutical companies
FIGURE 27 EUROPE: PLASMA COLLECTION, 2012–2021 (LITERS)
FIGURE 28 NORTH AMERICA: PLASMA COLLECTION, 2012–2021 (LITERS)
5.2.1.3 Rising demand for blood components and growing concerns regarding blood safety
5.2.1.4 Increase in complex surgical procedures
TABLE 2 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY
5.2.1.5 Favorable reimbursement policies for apheresis procedures
5.2.2 RESTRAINTS
5.2.2.1 High cost of procedures and installation through rental models
5.2.2.2 Limited use in blood donation due to low awareness
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION
5.2.2.3 Stringent donor recruitment criteria
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
5.2.2.4 Dearth of skilled professionals and low adoption of therapeutic apheresis
5.2.3 OPPORTUNITIES
5.2.3.1 Apheresis for leukemia and pediatric patients
5.2.3.2 Emerging economies with increasing investments from government bodies and leading players
5.2.4 CHALLENGES
5.2.4.1 Recruitment of voluntary non-remunerated donors
5.2.4.2 Safety of blood transfusion in developing countries
5.3 INDUSTRY TRENDS
FIGURE 29 FOCUS ON PERSONALIZED MEDICINE, AUTOMATION, EFFICIENCY, AND EXPANSION OF APHERESIS APPLICATIONS – LEADING TRENDS
5.3.1 INCREASE IN FOCUS ON PERSONALIZED MEDICINE
5.3.2 INCREASE IN FOCUS ON AUTOMATION AND EFFICIENCY
5.3.3 EXPANSION OF APHERESIS APPLICATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Centrifugation
5.4.1.2 Membrane Filtration
5.4.1.3 Automated collection systems
5.4.2 COMPLEMENTARY TECHNOLOGY
5.4.2.1 Biocompatible Materials
5.4.2.2 Automation and robotics
5.4.2.3 Advanced imaging technologies
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Extracorporeal Photopheresis (ECP)
5.4.3.2 Continuous Renal Replacement Therapy (CRRT)
5.4.3.3 Hemodialysis
5.5 VALUE CHAIN ANALYSIS
FIGURE 30 APHERESIS MARKET: VALUE CHAIN ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY ANALYSIS
5.7.1.1 North America
5.7.1.1.1 US
5.7.1.1.2 Canada
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.3.1 Japan
5.7.1.3.2 China
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR APHERESIS MARKET
FIGURE 31 GLOBAL NUMBER OF PATENTS PUBLICATIONS (JANUARY 2014?MARCH 2024)
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS (JANUARY 2014? MARCH 2024)
FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR APHERESIS (JANUARY 2013? MARCH 2024)
TABLE 11 LIST OF PATENTS IN APHERESIS MARKET, 2014–2024
5.9 HS CODES: APHERESIS INSTRUMENTS
TABLE 12 HS CODES FOR APHERESIS INSTRUMENTS
5.10 PRICING ANALYSIS
TABLE 13 PRICING OF APHERESIS PRODUCTS, 2023 (USD)
TABLE 14 PRICING ANALYSIS OF APHERESIS PRODUCTS (USD)
TABLE 15 REGIONAL PRICING ANALYSIS OF KEY APHERESIS PRODUCTS, 2023 (USD)
5.11 REIMBURSEMENT ANALYSIS
TABLE 16 REIMBURSEMENT ANALYSIS: FOR APHERESIS PROCEDURES
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
TABLE 17 APHERESIS MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
5.13.2 BUYING CRITERIA
FIGURE 35 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
TABLE 19 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
5.14 UNMET NEEDS IN APHERESIS MARKET
TABLE 20 UNMET NEEDS: APHERESIS MARKET
5.15 END USER EXPECTATIONS IN APHERESIS MARKET
TABLE 21 END USER EXPECTATIONS: APHERESIS MARKET
5.16 AI INTEGRATION IN APHERESIS MARKET
TABLE 22 AI INTEGRATION: APHERESIS MARKET
5.17 ECOSYSTEM ANALYSIS
FIGURE 36 APHERESIS MARKET: ECOSYSTEM
TABLE 23 ECOSYSTEM OF APHERESIS MARKET
5.18 CASE STUDIES
5.18.1 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18.2 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18.3 CASE STUDY 3: THERAPEUTIC PLASMA EXCHANGE FOR MYASTHENIA GRAVIS
5.18.4 CASE STUDY 4: THERAPEUTIC APHERESIS FOR TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)
5.19 SUPPLY CHAIN ANALYSIS
FIGURE 37 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
5.20 ADJACENT MARKET ANALYSIS
5.20.1 LEUKAPHERESIS MARKET
FIGURE 38 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW
FIGURE 39 LEUKOPAKS MARKET OVERVIEW
5.21 APHERESIS MARKET: INVESTMENT AND FUNDING SCENARIO
FIGURE 40 INVESTMENT AND FUNDING SCENARIO: APHERESIS MARKET (2018–2023)
6 APHERESIS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 24 APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
6.2 APHERESIS DISPOSABLES
6.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO BOOST GROWTH
TABLE 25 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 26 KEY PLAYERS PROVIDING APHERESIS DISPOSABLES
6.3 APHERESIS DEVICES
TABLE 27 APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 28 APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
6.3.1 CENTRIFUGAL APHERESIS DEVICES
6.3.1.1 Increasing installation in hospitals for therapeutic apheresis
TABLE 29 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 30 KEY PLAYERS PROVIDING CENTRIFUGAL APHERESIS DEVICES
6.3.2 MEMBRANE SEPARATORS
6.3.2.1 Separation of huge volumes of plasma from milliliters of whole blood – key limiting factor
TABLE 31 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 32 KEY PLAYERS PROVIDING MEMBRANE SEPARATORS
7 APHERESIS MARKET, BY PROCEDURE
7.1 INTRODUCTION
TABLE 33 APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
7.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS)
7.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH
TABLE 34 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS), BY COUNTRY, 2021–2029 (USD MILLION)
7.3 THERAPEUTIC APHERESIS
TABLE 35 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 36 THERAPEUTIC APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1 THERAPEUTIC APHERESIS DISPOSABLES
TABLE 37 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 38 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.1 Neurological disorders
7.3.1.1.1 Hold major share in therapeutic apheresis disposables market
TABLE 39 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.2 Blood disorders
7.3.1.2.1 Increasing prevalence of hematologic and genetic disorders to boost demand
TABLE 40 BLOOD DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.3 Renal disorders
7.3.1.3.1 Regarded among most useful treatment options for several renal disorders
TABLE 41 RENAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.4 Autoimmune disorders
7.3.1.4.1 Vital support component for treatment of autoimmune disorders
TABLE 42 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.5 Metabolic disorders
7.3.1.5.1 Increasing adoption for treatment of diabetes and other metabolic disorders
TABLE 43 METABOLIC DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.6 Cardiovascular disorders
7.3.1.6.1 Low-density lipoprotein (LDL) apheresis mainly used in treatment of cardiovascular disorders
TABLE 44 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.7 Other disorders
TABLE 45 OTHER DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.2 THERAPEUTIC APHERESIS DEVICES
7.3.2.1 Centrifugation-based devices – most commonly adopted
TABLE 46 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8 APHERESIS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 47 APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
8.2 CENTRIFUGATION
TABLE 48 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION
TABLE 49 KEY PLAYERS PROVIDING CENTRIFUGATION TECHNOLOGY
TABLE 50 CENTRIFUGATION: APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 51 CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.2.1 CONTINUOUS FLOW CENTRIFUGATION
8.2.1.1 Preferred in blood collection and therapeutic apheresis procedures
TABLE 52 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.2.2 INTERMITTENT FLOW CENTRIFUGATION
8.2.2.1 Need for single venipuncture site – major driving factor
TABLE 53 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.3 MEMBRANE SEPARATION
8.3.1 HIGH EFFICACY ACCOUNTS FOR HIGH USAGE IN DEVELOPED COUNTRIES
TABLE 54 SIZE OF BLOOD COMPONENTS
TABLE 55 KEY PLAYERS PROVIDING MEMBRANE SEPARATION TECHNOLOGY
TABLE 56 MEMBRANE SEPARATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9 APHERESIS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 57 APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
9.2 PLASMAPHERESIS
9.2.1 LARGEST APPLICATION SEGMENT IN APHERESIS MARKET
TABLE 58 PLASMAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.3 PLATELETPHERESIS
9.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE GROWTH
TABLE 59 PLATELETPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.4 ERYTHROCYTAPHERESIS
9.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE GROWTH
TABLE 60 ERYTHROCYTAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.5 LEUKAPHERESIS
9.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE SEGMENT
TABLE 61 LEUKAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.6 PHOTOPHERESIS
9.6.1 INCREASING PREVALENCE OF BLOOD DISORDERS AND ORGAN TRANSPLANT REJECTION TO DRIVE SEGMENT
TABLE 62 PHOTOPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 63 OTHER APPLICATIONS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10 APHERESIS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 64 APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
10.2.1 INCREASING AWARENESS OF BENEFITS OF APHERESIS TO FUEL SEGMENT
TABLE 65 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10.3 HOSPITALS & TRANSFUSION CENTERS
10.3.1 RISING NUMBER OF COMPLEX SURGICAL PROCEDURES AND TRANSFUSIONS TO BOOST MARKET
TABLE 66 HOSPITALS & TRANSFUSION CENTERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 67 OTHER END USERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
11 APHERESIS MARKET, BY REGION
11.1 INTRODUCTION
FIGURE 41 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT
TABLE 68 APHERESIS MARKET, BY REGION, 2021–2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 42 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 70 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 71 NORTH AMERICA: DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 73 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.2.2 US
11.2.2.1 Dominates North American apheresis market
TABLE 79 US: KEY MACROINDICATORS
TABLE 80 US: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 81 US: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 82 US: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 83 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 84 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 85 US: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 86 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 87 US: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 88 US: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising demand for plasma protein products to drive market growth
TABLE 89 CANADA: KEY MACROINDICATORS
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 91 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 93 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 94 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 95 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 96 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 97 CANADA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 98 CANADA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 99 EUROPE: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 100 EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 101 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 102 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 103 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 104 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 105 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 106 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 107 EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 108 EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Fastest-growing market for apheresis systems in Europe
TABLE 109 GERMANY: KEY MACROINDICATORS
TABLE 110 GERMANY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 111 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 112 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 113 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 114 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 115 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 116 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 117 GERMANY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 118 GERMANY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing need for blood components to boost market
TABLE 119 FRANCE: KEY MACROINDICATORS
TABLE 120 FRANCE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 121 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 122 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 123 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 124 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 125 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 126 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 127 FRANCE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 128 FRANCE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Therapeutic plasma exchange and LDL apheresis - widely adopted procedures
TABLE 129 ITALY: KEY MACROINDICATORS
TABLE 130 ITALY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 131 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 132 ITALY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 133 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 134 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 135 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 136 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 137 ITALY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 138 ITALY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.5 UK
11.3.5.1 Growing consumption of plasma-derived products to fuel market growth
TABLE 139 UK: KEY MACROINDICATORS
TABLE 140 UK: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 141 UK: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 142 UK: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 143 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2021–2029 (USD MILLION)
TABLE 144 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 145 UK: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 146 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 147 UK: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 148 UK: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for treatment of chronic diseases in the elderly
TABLE 149 SPAIN: KEY MACROINDICATORS
TABLE 150 SPAIN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 151 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 152 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 153 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 154 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 155 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 156 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 157 SPAIN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 158 SPAIN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 159 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 160 REST OF EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 161 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 162 REST OF EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 163 REST OF EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 164 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 165 REST OF EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 166 REST OF EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 167 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 43 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
TABLE 168 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 170 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 172 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Dominant Asia Pacific apheresis market
TABLE 178 CHINA: KEY MACROINDICATORS
TABLE 179 CHINA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 180 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 181 CHINA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 182 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 183 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 184 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 185 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 186 CHINA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 187 CHINA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Advanced technology and universal healthcare insurance – key drivers
TABLE 188 JAPAN: KEY MACROINDICATORS
TABLE 189 JAPAN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 190 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 191 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 192 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 193 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 194 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 195 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 196 JAPAN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 197 JAPAN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increasing demand for blood components and growing applications of plasma derivatives – key drivers
TABLE 198 INDIA: KEY MACROINDICATORS
TABLE 199 INDIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 200 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 201 INDIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 202 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 203 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 204 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 205 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 206 INDIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 207 INDIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Growing awareness campaigns to drive market growth
TABLE 208 AUSTRALIA: KEY MACROINDICATORS
TABLE 209 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 210 AUSTRALIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 211 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 212 AUSTRALIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 213 AUSTRALIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 214 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 215 AUSTRALIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 216 AUSTRALIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 217 AUSTRALIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rise in prevalence of blood cancers to drive market growth
TABLE 218 SOUTH KOREA: KEY MACROINDICATORS
TABLE 219 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 220 SOUTH KOREA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 221 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 222 SOUTH KOREA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 223 SOUTH KOREA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 224 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 225 SOUTH KOREA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 226 SOUTH KOREA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 227 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 228 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 229 REST OF ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 230 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 237 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 238 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 239 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 240 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 241 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 242 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 243 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 245 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 246 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Accounts for largest share of Latin American market
TABLE 247 BRAZIL: KEY MACROINDICATORS
TABLE 248 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 249 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 250 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 251 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 252 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 253 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 254 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 255 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 256 BRAZIL: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Rapidly growing geriatric population – key factor driving market growth
TABLE 257 MEXICO: KEY MACROINDICATORS
TABLE 258 MEXICO: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 259 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 260 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 261 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 262 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 263 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 264 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 265 MEXICO: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 266 MEXICO: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 267 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 268 REST OF LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 276 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6.2 GCC COUNTRIES
11.6.2.1 Increase in prevalence of chronic diseases to drive market
TABLE 286 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 287 GCC COUNTRIES: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 288 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 289 GCC COUNTRIES: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 290 GCC COUNTRIES: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 291 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 292 GCC COUNTRIES: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 293 GCC COUNTRIES: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 294 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 295 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 296 REST OF MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 297 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 298 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 299 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 300 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 301 REST OF MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 302 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 303 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES
FIGURE 44 OVERVIEW OF STRATEGIES DEPLOYED BY APHERESIS MARKET PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 45 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2023)
12.4 MARKET SHARE ANALYSIS
12.4.1 APHERESIS MARKET SHARE ANALYSIS
FIGURE 46 APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 304 APHERESIS MARKET: DEGREE OF COMPETITION
12.4.2 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS
FIGURE 47 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 305 CENTRIFUGATION MARKET: DEGREE OF COMPETITION
12.4.3 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS
FIGURE 48 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 306 MEMBRANE SEPARATION MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 49 APHERESIS MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS, 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
FIGURE 50 APHERESIS MARKET: COMPANY FOOTPRINT
12.5.5.2 Region footprint
TABLE 307 APHERESIS MARKET: REGION FOOTPRINT
12.5.5.3 Product footprint
TABLE 308 APHERESIS MARKET: PRODUCT FOOTPRINT
12.5.5.4 Procedure footprint
TABLE 309 APHERESIS MARKET: PROCEDURE FOOTPRINT
12.5.5.5 Technology footprint
TABLE 310 APHERESIS MARKET: TECHNOLOGY FOOTPRINT
12.5.5.6 Application footprint
TABLE 311 APHERESIS MARKET: APPLICATION FOOTPRINT
12.5.5.7 End user footprint
TABLE 312 APHERESIS MARKET: END USER FOOTPRINT
12.6 COMPANY EVALUATION MATRIX, START-UP/SMES (2023)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 DYNAMIC COMPANIES
12.6.3 RESPONSIVE COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 51 APHERESIS MARKET: COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023
12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
TABLE 313 APHERESIS MARKET: KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO AND TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 314 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–FEBRUARY 2024
12.7.2 DEALS
TABLE 315 APHERESIS MARKET: DEALS, JANUARY 2020–FEBRUARY 2024
12.7.3 OTHERS
TABLE 316 APHERESIS MARKET: OTHERS, JANUARY 2020–FEBRUARY 2024
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
TABLE 317 APHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 TERUMO BCT, INC.
TABLE 318 TERUMO BCT, INC.: BUSINESS OVERVIEW
FIGURE 52 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
TABLE 319 TERUMO BCT, INC.: PRODUCTS & SERVICES OFFERED
TABLE 320 TERUMO BCT, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 321 TERUMO BCT, INC.: DEALS
TABLE 322 TERUMO BCT, INC.: EXPANSIONS
13.1.2 FRESENIUS SE &CO. KGAA
TABLE 323 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 53 FRESENIUS SE & CO KGAA: COMPANY SNAPSHOT (2022)
TABLE 324 FRESENIUS SE &CO. KGAA: PRODUCTS & SERVICES OFFERED
TABLE 325 FRESENIUS SE &CO. KGAA: PRODUCT LAUNCHES & APPROVALS
TABLE 326 FRESENIUS SE &CO. KGAA: DEALS
TABLE 327 FRESENIUS SE &CO. KGAA: EXPANSIONS
13.1.3 HAEMONETICS CORPORATION
TABLE 328 HAEMONETICS CORPORATION: BUSINESS OVERVIEW
FIGURE 54 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 329 HAEMONETICS CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 330 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 331 HAEMONETICS CORPORATION: DEALS
TABLE 332 HAEMONETICS CORPORATION: EXPANSIONS
13.1.4 BAXTER INTERNATIONAL INC.
TABLE 333 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
FIGURE 55 BAXTER INTERNATIONAL INC: COMPANY SNAPSHOT (2023)
TABLE 334 BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES OFFERED
TABLE 335 BAXTER INTERNATIONAL INC: OTHERS
13.1.5 ASAHI KASEI MEDICAL CO., LTD. (SUBSIDIARY OF ASAHI KASEI CORPORATION)
TABLE 336 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 56 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 337 ASAHI KASEI CORPORATION: PRODUCTS & SERVICES OFFERED
13.1.6 B. BRAUN MELSUNGEN AG
TABLE 338 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 57 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
TABLE 339 B. BRAUN MELSUNGEN AG: PRODUCTS & SERVICES OFFERED
TABLE 340 B. BRAUN MELSUNGEN AG: DEALS
TABLE 341 B. BRAUN MELSUNGEN AG: OTHERS
13.1.7 CERUS CORPORATION
TABLE 342 CERUS CORPORATION: BUSINESS OVERVIEW
FIGURE 58 CERUS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 343 CERUS CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 344 CERUS CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 345 CERUS CORPORATION: DEALS
TABLE 346 CERUS CORPORATION: OTHERS
13.1.8 KANEKA CORPORATION
TABLE 347 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 59 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 348 KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 349 KANEKA CORPORATION: DEALS
TABLE 350 KANEKA CORPORATION: OTHERS
13.1.9 SB-KAWASUMI LABORATORIES, INC. (SUBSIDIARY OF SUMITOMO BAKELITE CO., LTD.)
TABLE 351 SB-KAWASUMI LABORATORIES: BUSINESS OVERVIEW
FIGURE 60 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2023)
TABLE 352 SB-KAWASUMI LABORATORIES: PRODUCTS & SERVICES OFFERED
13.1.10 NIKKISO CO., LTD.
TABLE 353 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 61 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 354 NIKKISO CO., LTD: PRODUCTS & SERVICES OFFERED
13.1.11 MACOPHARMA SA
TABLE 355 MACOPHARMA SA: BUSINESS OVERVIEW
TABLE 356 MACOPHARMA SA: PRODUCTS & SERVICES OFFERED
13.1.12 MILTENYI BIOTEC
TABLE 357 MILTENYI BIOTEC: BUSINESS OVERVIEW
TABLE 358 MILTENYI BIOTEC: PRODUCTS & SERVICES OFFERED
13.1.13 OTSUKA HOLDINGS CO., LTD.
TABLE 359 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
FIGURE 62 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 360 OTSUKA HOLDINGS CO., LTD.: PRODUCTS & SERVICES OFFERED
13.1.14 MEDICA S.P.A.
TABLE 361 MEDICA S.P.A: BUSINESS OVERVIEW
TABLE 362 MEDICA S.P.A: PRODUCTS & SERVICES OFFERED
TABLE 363 MEDICA S.P.A: EXPANSIONS
13.1.15 MALLINCKRODT PLC
TABLE 364 MALLINCKRODT PLC: BUSINESS OVERVIEW
FIGURE 63 MALLINCKRODT PLC: COMPANY SNAPSHOT (2022)
TABLE 365 MALLINCKRODT PLC: PRODUCTS & SERVICES OFFERED
TABLE 366 MALLINCKRODT PLC: PRODUCT LAUNCHES & APPROVALS
13.1.16 BECTON, DICKINSON AND COMPANY
TABLE 367 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
13.1.17 LMB TECHNOLOGIE GMBH
TABLE 369 LMB TECHNOLOGIE GMBH: BUSINESS OVERVIEW
TABLE 370 LMB TECHNOLOGIE GMBH: PRODUCTS & SERVICES OFFERED
13.1.18 BIOELETTRONICA S.R.L.
TABLE 371 BIOELETTRONICA S.R.L.: BUSINESS OVERVIEW
TABLE 372 BIOELETTRONICA S.R.L: PRODUCTS & SERVICES OFFERED
13.1.19 INFOMED SA
TABLE 373 INFOMED SA: BUSINESS OVERVIEW
TABLE 374 INFOMED SA: PRODUCTS & SERVICES OFFERED
13.1.20 CYTOSORBENTS CORPORATION
TABLE 375 CYTOSORBENTS CORPORATION: BUSINESS OVERVIEW
FIGURE 65 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 376 CYTOSORBENTS CORPORATION: PRODUCTS & SERVICES OFFERED
13.2 OTHER PLAYERS
13.2.1 MEDICAP CLINIC GMBH
13.2.2 HAIER BIOMEDICAL
13.2.3 BEIJING ZKSK TECHNOLOGY CO., LTD.
13.2.4 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD
13.2.5 PURIBLOOD MEDICAL
*Details on Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 PRODUCT DEFINITION
1.2.2 TECHNOLOGY DEFINITION
1.2.3 APPLICATION DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
TABLE 1 CURRENCY CONVERSION RATES
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT
FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029): IMPACT LEVEL
FIGURE 8 CAGR PROJECTIONS
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 APHERESIS DISPOSABLES TO BE LARGEST SEGMENT DURING FORECAST PERIOD
FIGURE 11 CENTRIFUGAL APHERESIS DEVICES SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD
FIGURE 12 AUTOMATED BLOOD COLLECTION TO BE LEADING SEGMENT DURING FORECAST PERIOD
FIGURE 13 THERAPEUTIC APHERESIS DISPOSABLES TO HOLD DOMINANT SHARE BY 2029
FIGURE 14 NEUROLOGICAL DISORDERS TO BE LEADING SEGMENT DURING FORECAST PERIOD
FIGURE 15 CENTRIFUGATION TECHNOLOGY TO DOMINATE APHERESIS MARKET DURING FORECAST PERIOD
FIGURE 16 CONTINUOUS FLOW CENTRIFUGATION TO BE MAJOR SEGMENT DURING FORECAST PERIOD
FIGURE 17 PLASMAPHERESIS SEGMENT TO HOLD LARGEST SHARE BY 2029
FIGURE 18 COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS – MAJOR SEGMENT BY 2029
FIGURE 19 ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR APHERESIS
4 PREMIUM INSIGHTS
4.1 APHERESIS MARKET OVERVIEW
FIGURE 20 RISING PREVALENCE OF DISEASES AND GROWING NUMBER OF TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION & COUNTRY
FIGURE 21 PLASMAPHERESIS AND GERMANY ACCOUNTED FOR LARGEST SHARE OF EUROPEAN APHERESIS MARKET IN 2023
4.3 REGIONAL SNAPSHOT OF APHERESIS MARKET (2023)
FIGURE 22 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
4.4 REGIONAL MIX: APHERESIS MARKET, 2024–2029 (USD MILLION)
FIGURE 23 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)
FIGURE 24 DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 25 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases and trauma/injury cases
FIGURE 26 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS)
5.2.1.2 Increasing demand for source plasma from biopharmaceutical companies
FIGURE 27 EUROPE: PLASMA COLLECTION, 2012–2021 (LITERS)
FIGURE 28 NORTH AMERICA: PLASMA COLLECTION, 2012–2021 (LITERS)
5.2.1.3 Rising demand for blood components and growing concerns regarding blood safety
5.2.1.4 Increase in complex surgical procedures
TABLE 2 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY
5.2.1.5 Favorable reimbursement policies for apheresis procedures
5.2.2 RESTRAINTS
5.2.2.1 High cost of procedures and installation through rental models
5.2.2.2 Limited use in blood donation due to low awareness
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION
5.2.2.3 Stringent donor recruitment criteria
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
5.2.2.4 Dearth of skilled professionals and low adoption of therapeutic apheresis
5.2.3 OPPORTUNITIES
5.2.3.1 Apheresis for leukemia and pediatric patients
5.2.3.2 Emerging economies with increasing investments from government bodies and leading players
5.2.4 CHALLENGES
5.2.4.1 Recruitment of voluntary non-remunerated donors
5.2.4.2 Safety of blood transfusion in developing countries
5.3 INDUSTRY TRENDS
FIGURE 29 FOCUS ON PERSONALIZED MEDICINE, AUTOMATION, EFFICIENCY, AND EXPANSION OF APHERESIS APPLICATIONS – LEADING TRENDS
5.3.1 INCREASE IN FOCUS ON PERSONALIZED MEDICINE
5.3.2 INCREASE IN FOCUS ON AUTOMATION AND EFFICIENCY
5.3.3 EXPANSION OF APHERESIS APPLICATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Centrifugation
5.4.1.2 Membrane Filtration
5.4.1.3 Automated collection systems
5.4.2 COMPLEMENTARY TECHNOLOGY
5.4.2.1 Biocompatible Materials
5.4.2.2 Automation and robotics
5.4.2.3 Advanced imaging technologies
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Extracorporeal Photopheresis (ECP)
5.4.3.2 Continuous Renal Replacement Therapy (CRRT)
5.4.3.3 Hemodialysis
5.5 VALUE CHAIN ANALYSIS
FIGURE 30 APHERESIS MARKET: VALUE CHAIN ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY ANALYSIS
5.7.1.1 North America
5.7.1.1.1 US
5.7.1.1.2 Canada
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.3.1 Japan
5.7.1.3.2 China
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR APHERESIS MARKET
FIGURE 31 GLOBAL NUMBER OF PATENTS PUBLICATIONS (JANUARY 2014?MARCH 2024)
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS (JANUARY 2014? MARCH 2024)
FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR APHERESIS (JANUARY 2013? MARCH 2024)
TABLE 11 LIST OF PATENTS IN APHERESIS MARKET, 2014–2024
5.9 HS CODES: APHERESIS INSTRUMENTS
TABLE 12 HS CODES FOR APHERESIS INSTRUMENTS
5.10 PRICING ANALYSIS
TABLE 13 PRICING OF APHERESIS PRODUCTS, 2023 (USD)
TABLE 14 PRICING ANALYSIS OF APHERESIS PRODUCTS (USD)
TABLE 15 REGIONAL PRICING ANALYSIS OF KEY APHERESIS PRODUCTS, 2023 (USD)
5.11 REIMBURSEMENT ANALYSIS
TABLE 16 REIMBURSEMENT ANALYSIS: FOR APHERESIS PROCEDURES
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
TABLE 17 APHERESIS MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR APHERESIS PRODUCTS
5.13.2 BUYING CRITERIA
FIGURE 35 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
TABLE 19 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS
5.14 UNMET NEEDS IN APHERESIS MARKET
TABLE 20 UNMET NEEDS: APHERESIS MARKET
5.15 END USER EXPECTATIONS IN APHERESIS MARKET
TABLE 21 END USER EXPECTATIONS: APHERESIS MARKET
5.16 AI INTEGRATION IN APHERESIS MARKET
TABLE 22 AI INTEGRATION: APHERESIS MARKET
5.17 ECOSYSTEM ANALYSIS
FIGURE 36 APHERESIS MARKET: ECOSYSTEM
TABLE 23 ECOSYSTEM OF APHERESIS MARKET
5.18 CASE STUDIES
5.18.1 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18.2 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18.3 CASE STUDY 3: THERAPEUTIC PLASMA EXCHANGE FOR MYASTHENIA GRAVIS
5.18.4 CASE STUDY 4: THERAPEUTIC APHERESIS FOR TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)
5.19 SUPPLY CHAIN ANALYSIS
FIGURE 37 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
5.20 ADJACENT MARKET ANALYSIS
5.20.1 LEUKAPHERESIS MARKET
FIGURE 38 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW
FIGURE 39 LEUKOPAKS MARKET OVERVIEW
5.21 APHERESIS MARKET: INVESTMENT AND FUNDING SCENARIO
FIGURE 40 INVESTMENT AND FUNDING SCENARIO: APHERESIS MARKET (2018–2023)
6 APHERESIS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 24 APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
6.2 APHERESIS DISPOSABLES
6.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO BOOST GROWTH
TABLE 25 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 26 KEY PLAYERS PROVIDING APHERESIS DISPOSABLES
6.3 APHERESIS DEVICES
TABLE 27 APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 28 APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
6.3.1 CENTRIFUGAL APHERESIS DEVICES
6.3.1.1 Increasing installation in hospitals for therapeutic apheresis
TABLE 29 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 30 KEY PLAYERS PROVIDING CENTRIFUGAL APHERESIS DEVICES
6.3.2 MEMBRANE SEPARATORS
6.3.2.1 Separation of huge volumes of plasma from milliliters of whole blood – key limiting factor
TABLE 31 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 32 KEY PLAYERS PROVIDING MEMBRANE SEPARATORS
7 APHERESIS MARKET, BY PROCEDURE
7.1 INTRODUCTION
TABLE 33 APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
7.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS)
7.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH
TABLE 34 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS), BY COUNTRY, 2021–2029 (USD MILLION)
7.3 THERAPEUTIC APHERESIS
TABLE 35 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 36 THERAPEUTIC APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1 THERAPEUTIC APHERESIS DISPOSABLES
TABLE 37 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 38 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.1 Neurological disorders
7.3.1.1.1 Hold major share in therapeutic apheresis disposables market
TABLE 39 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.2 Blood disorders
7.3.1.2.1 Increasing prevalence of hematologic and genetic disorders to boost demand
TABLE 40 BLOOD DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.3 Renal disorders
7.3.1.3.1 Regarded among most useful treatment options for several renal disorders
TABLE 41 RENAL DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.4 Autoimmune disorders
7.3.1.4.1 Vital support component for treatment of autoimmune disorders
TABLE 42 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.5 Metabolic disorders
7.3.1.5.1 Increasing adoption for treatment of diabetes and other metabolic disorders
TABLE 43 METABOLIC DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.6 Cardiovascular disorders
7.3.1.6.1 Low-density lipoprotein (LDL) apheresis mainly used in treatment of cardiovascular disorders
TABLE 44 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.1.7 Other disorders
TABLE 45 OTHER DISORDERS: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
7.3.2 THERAPEUTIC APHERESIS DEVICES
7.3.2.1 Centrifugation-based devices – most commonly adopted
TABLE 46 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8 APHERESIS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 47 APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
8.2 CENTRIFUGATION
TABLE 48 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION
TABLE 49 KEY PLAYERS PROVIDING CENTRIFUGATION TECHNOLOGY
TABLE 50 CENTRIFUGATION: APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 51 CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.2.1 CONTINUOUS FLOW CENTRIFUGATION
8.2.1.1 Preferred in blood collection and therapeutic apheresis procedures
TABLE 52 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.2.2 INTERMITTENT FLOW CENTRIFUGATION
8.2.2.1 Need for single venipuncture site – major driving factor
TABLE 53 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
8.3 MEMBRANE SEPARATION
8.3.1 HIGH EFFICACY ACCOUNTS FOR HIGH USAGE IN DEVELOPED COUNTRIES
TABLE 54 SIZE OF BLOOD COMPONENTS
TABLE 55 KEY PLAYERS PROVIDING MEMBRANE SEPARATION TECHNOLOGY
TABLE 56 MEMBRANE SEPARATION: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9 APHERESIS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 57 APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
9.2 PLASMAPHERESIS
9.2.1 LARGEST APPLICATION SEGMENT IN APHERESIS MARKET
TABLE 58 PLASMAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.3 PLATELETPHERESIS
9.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE GROWTH
TABLE 59 PLATELETPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.4 ERYTHROCYTAPHERESIS
9.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE GROWTH
TABLE 60 ERYTHROCYTAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.5 LEUKAPHERESIS
9.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE SEGMENT
TABLE 61 LEUKAPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.6 PHOTOPHERESIS
9.6.1 INCREASING PREVALENCE OF BLOOD DISORDERS AND ORGAN TRANSPLANT REJECTION TO DRIVE SEGMENT
TABLE 62 PHOTOPHERESIS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 63 OTHER APPLICATIONS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10 APHERESIS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 64 APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
10.2.1 INCREASING AWARENESS OF BENEFITS OF APHERESIS TO FUEL SEGMENT
TABLE 65 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10.3 HOSPITALS & TRANSFUSION CENTERS
10.3.1 RISING NUMBER OF COMPLEX SURGICAL PROCEDURES AND TRANSFUSIONS TO BOOST MARKET
TABLE 66 HOSPITALS & TRANSFUSION CENTERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 67 OTHER END USERS: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
11 APHERESIS MARKET, BY REGION
11.1 INTRODUCTION
FIGURE 41 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT
TABLE 68 APHERESIS MARKET, BY REGION, 2021–2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 42 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 70 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 71 NORTH AMERICA: DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 73 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.2.2 US
11.2.2.1 Dominates North American apheresis market
TABLE 79 US: KEY MACROINDICATORS
TABLE 80 US: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 81 US: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 82 US: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 83 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 84 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 85 US: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 86 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 87 US: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 88 US: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising demand for plasma protein products to drive market growth
TABLE 89 CANADA: KEY MACROINDICATORS
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 91 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 93 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 94 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 95 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 96 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 97 CANADA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 98 CANADA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 99 EUROPE: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 100 EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 101 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 102 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 103 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 104 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 105 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 106 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 107 EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 108 EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Fastest-growing market for apheresis systems in Europe
TABLE 109 GERMANY: KEY MACROINDICATORS
TABLE 110 GERMANY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 111 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 112 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 113 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 114 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 115 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 116 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 117 GERMANY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 118 GERMANY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing need for blood components to boost market
TABLE 119 FRANCE: KEY MACROINDICATORS
TABLE 120 FRANCE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 121 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 122 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 123 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 124 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 125 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 126 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 127 FRANCE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 128 FRANCE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Therapeutic plasma exchange and LDL apheresis - widely adopted procedures
TABLE 129 ITALY: KEY MACROINDICATORS
TABLE 130 ITALY: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 131 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 132 ITALY: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 133 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 134 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 135 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 136 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 137 ITALY: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 138 ITALY: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.5 UK
11.3.5.1 Growing consumption of plasma-derived products to fuel market growth
TABLE 139 UK: KEY MACROINDICATORS
TABLE 140 UK: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 141 UK: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 142 UK: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 143 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2021–2029 (USD MILLION)
TABLE 144 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 145 UK: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 146 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 147 UK: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 148 UK: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for treatment of chronic diseases in the elderly
TABLE 149 SPAIN: KEY MACROINDICATORS
TABLE 150 SPAIN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 151 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 152 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 153 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 154 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 155 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 156 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 157 SPAIN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 158 SPAIN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 159 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 160 REST OF EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 161 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 162 REST OF EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 163 REST OF EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 164 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 165 REST OF EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 166 REST OF EUROPE: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 167 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 43 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
TABLE 168 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 170 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 172 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Dominant Asia Pacific apheresis market
TABLE 178 CHINA: KEY MACROINDICATORS
TABLE 179 CHINA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 180 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 181 CHINA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 182 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 183 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 184 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 185 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 186 CHINA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 187 CHINA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Advanced technology and universal healthcare insurance – key drivers
TABLE 188 JAPAN: KEY MACROINDICATORS
TABLE 189 JAPAN: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 190 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 191 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 192 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 193 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 194 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 195 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 196 JAPAN: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 197 JAPAN: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increasing demand for blood components and growing applications of plasma derivatives – key drivers
TABLE 198 INDIA: KEY MACROINDICATORS
TABLE 199 INDIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 200 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 201 INDIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 202 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 203 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 204 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 205 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 206 INDIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 207 INDIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Growing awareness campaigns to drive market growth
TABLE 208 AUSTRALIA: KEY MACROINDICATORS
TABLE 209 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 210 AUSTRALIA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 211 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 212 AUSTRALIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 213 AUSTRALIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 214 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 215 AUSTRALIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 216 AUSTRALIA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 217 AUSTRALIA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rise in prevalence of blood cancers to drive market growth
TABLE 218 SOUTH KOREA: KEY MACROINDICATORS
TABLE 219 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 220 SOUTH KOREA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 221 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 222 SOUTH KOREA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 223 SOUTH KOREA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 224 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 225 SOUTH KOREA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 226 SOUTH KOREA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 227 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 228 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 229 REST OF ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 230 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 237 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 238 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 239 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 240 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 241 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 242 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 243 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 245 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 246 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Accounts for largest share of Latin American market
TABLE 247 BRAZIL: KEY MACROINDICATORS
TABLE 248 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 249 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 250 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 251 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 252 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 253 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 254 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 255 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 256 BRAZIL: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Rapidly growing geriatric population – key factor driving market growth
TABLE 257 MEXICO: KEY MACROINDICATORS
TABLE 258 MEXICO: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 259 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 260 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 261 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 262 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 263 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 264 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 265 MEXICO: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 266 MEXICO: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 267 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 268 REST OF LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 276 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6.2 GCC COUNTRIES
11.6.2.1 Increase in prevalence of chronic diseases to drive market
TABLE 286 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 287 GCC COUNTRIES: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 288 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 289 GCC COUNTRIES: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 290 GCC COUNTRIES: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 291 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 292 GCC COUNTRIES: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 293 GCC COUNTRIES: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 294 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
11.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 295 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 296 REST OF MIDDLE EAST & AFRICA: APHERESIS DEVICES MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 297 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2021–2029 (USD MILLION)
TABLE 298 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
TABLE 299 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2021–2029 (USD MILLION)
TABLE 300 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
TABLE 301 REST OF MIDDLE EAST & AFRICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2021–2029 (USD MILLION)
TABLE 302 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
TABLE 303 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2021–2029 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES
FIGURE 44 OVERVIEW OF STRATEGIES DEPLOYED BY APHERESIS MARKET PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 45 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2023)
12.4 MARKET SHARE ANALYSIS
12.4.1 APHERESIS MARKET SHARE ANALYSIS
FIGURE 46 APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 304 APHERESIS MARKET: DEGREE OF COMPETITION
12.4.2 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS
FIGURE 47 CENTRIFUGATION: APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 305 CENTRIFUGATION MARKET: DEGREE OF COMPETITION
12.4.3 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS
FIGURE 48 MEMBRANE SEPARATION: APHERESIS MARKET SHARE ANALYSIS (2023)
TABLE 306 MEMBRANE SEPARATION MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 49 APHERESIS MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS, 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
FIGURE 50 APHERESIS MARKET: COMPANY FOOTPRINT
12.5.5.2 Region footprint
TABLE 307 APHERESIS MARKET: REGION FOOTPRINT
12.5.5.3 Product footprint
TABLE 308 APHERESIS MARKET: PRODUCT FOOTPRINT
12.5.5.4 Procedure footprint
TABLE 309 APHERESIS MARKET: PROCEDURE FOOTPRINT
12.5.5.5 Technology footprint
TABLE 310 APHERESIS MARKET: TECHNOLOGY FOOTPRINT
12.5.5.6 Application footprint
TABLE 311 APHERESIS MARKET: APPLICATION FOOTPRINT
12.5.5.7 End user footprint
TABLE 312 APHERESIS MARKET: END USER FOOTPRINT
12.6 COMPANY EVALUATION MATRIX, START-UP/SMES (2023)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 DYNAMIC COMPANIES
12.6.3 RESPONSIVE COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 51 APHERESIS MARKET: COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023
12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
TABLE 313 APHERESIS MARKET: KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO AND TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 314 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–FEBRUARY 2024
12.7.2 DEALS
TABLE 315 APHERESIS MARKET: DEALS, JANUARY 2020–FEBRUARY 2024
12.7.3 OTHERS
TABLE 316 APHERESIS MARKET: OTHERS, JANUARY 2020–FEBRUARY 2024
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
TABLE 317 APHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 TERUMO BCT, INC.
TABLE 318 TERUMO BCT, INC.: BUSINESS OVERVIEW
FIGURE 52 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
TABLE 319 TERUMO BCT, INC.: PRODUCTS & SERVICES OFFERED
TABLE 320 TERUMO BCT, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 321 TERUMO BCT, INC.: DEALS
TABLE 322 TERUMO BCT, INC.: EXPANSIONS
13.1.2 FRESENIUS SE &CO. KGAA
TABLE 323 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 53 FRESENIUS SE & CO KGAA: COMPANY SNAPSHOT (2022)
TABLE 324 FRESENIUS SE &CO. KGAA: PRODUCTS & SERVICES OFFERED
TABLE 325 FRESENIUS SE &CO. KGAA: PRODUCT LAUNCHES & APPROVALS
TABLE 326 FRESENIUS SE &CO. KGAA: DEALS
TABLE 327 FRESENIUS SE &CO. KGAA: EXPANSIONS
13.1.3 HAEMONETICS CORPORATION
TABLE 328 HAEMONETICS CORPORATION: BUSINESS OVERVIEW
FIGURE 54 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 329 HAEMONETICS CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 330 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 331 HAEMONETICS CORPORATION: DEALS
TABLE 332 HAEMONETICS CORPORATION: EXPANSIONS
13.1.4 BAXTER INTERNATIONAL INC.
TABLE 333 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
FIGURE 55 BAXTER INTERNATIONAL INC: COMPANY SNAPSHOT (2023)
TABLE 334 BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES OFFERED
TABLE 335 BAXTER INTERNATIONAL INC: OTHERS
13.1.5 ASAHI KASEI MEDICAL CO., LTD. (SUBSIDIARY OF ASAHI KASEI CORPORATION)
TABLE 336 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 56 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 337 ASAHI KASEI CORPORATION: PRODUCTS & SERVICES OFFERED
13.1.6 B. BRAUN MELSUNGEN AG
TABLE 338 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 57 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
TABLE 339 B. BRAUN MELSUNGEN AG: PRODUCTS & SERVICES OFFERED
TABLE 340 B. BRAUN MELSUNGEN AG: DEALS
TABLE 341 B. BRAUN MELSUNGEN AG: OTHERS
13.1.7 CERUS CORPORATION
TABLE 342 CERUS CORPORATION: BUSINESS OVERVIEW
FIGURE 58 CERUS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 343 CERUS CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 344 CERUS CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 345 CERUS CORPORATION: DEALS
TABLE 346 CERUS CORPORATION: OTHERS
13.1.8 KANEKA CORPORATION
TABLE 347 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 59 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 348 KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 349 KANEKA CORPORATION: DEALS
TABLE 350 KANEKA CORPORATION: OTHERS
13.1.9 SB-KAWASUMI LABORATORIES, INC. (SUBSIDIARY OF SUMITOMO BAKELITE CO., LTD.)
TABLE 351 SB-KAWASUMI LABORATORIES: BUSINESS OVERVIEW
FIGURE 60 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2023)
TABLE 352 SB-KAWASUMI LABORATORIES: PRODUCTS & SERVICES OFFERED
13.1.10 NIKKISO CO., LTD.
TABLE 353 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 61 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 354 NIKKISO CO., LTD: PRODUCTS & SERVICES OFFERED
13.1.11 MACOPHARMA SA
TABLE 355 MACOPHARMA SA: BUSINESS OVERVIEW
TABLE 356 MACOPHARMA SA: PRODUCTS & SERVICES OFFERED
13.1.12 MILTENYI BIOTEC
TABLE 357 MILTENYI BIOTEC: BUSINESS OVERVIEW
TABLE 358 MILTENYI BIOTEC: PRODUCTS & SERVICES OFFERED
13.1.13 OTSUKA HOLDINGS CO., LTD.
TABLE 359 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
FIGURE 62 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2022)
TABLE 360 OTSUKA HOLDINGS CO., LTD.: PRODUCTS & SERVICES OFFERED
13.1.14 MEDICA S.P.A.
TABLE 361 MEDICA S.P.A: BUSINESS OVERVIEW
TABLE 362 MEDICA S.P.A: PRODUCTS & SERVICES OFFERED
TABLE 363 MEDICA S.P.A: EXPANSIONS
13.1.15 MALLINCKRODT PLC
TABLE 364 MALLINCKRODT PLC: BUSINESS OVERVIEW
FIGURE 63 MALLINCKRODT PLC: COMPANY SNAPSHOT (2022)
TABLE 365 MALLINCKRODT PLC: PRODUCTS & SERVICES OFFERED
TABLE 366 MALLINCKRODT PLC: PRODUCT LAUNCHES & APPROVALS
13.1.16 BECTON, DICKINSON AND COMPANY
TABLE 367 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
13.1.17 LMB TECHNOLOGIE GMBH
TABLE 369 LMB TECHNOLOGIE GMBH: BUSINESS OVERVIEW
TABLE 370 LMB TECHNOLOGIE GMBH: PRODUCTS & SERVICES OFFERED
13.1.18 BIOELETTRONICA S.R.L.
TABLE 371 BIOELETTRONICA S.R.L.: BUSINESS OVERVIEW
TABLE 372 BIOELETTRONICA S.R.L: PRODUCTS & SERVICES OFFERED
13.1.19 INFOMED SA
TABLE 373 INFOMED SA: BUSINESS OVERVIEW
TABLE 374 INFOMED SA: PRODUCTS & SERVICES OFFERED
13.1.20 CYTOSORBENTS CORPORATION
TABLE 375 CYTOSORBENTS CORPORATION: BUSINESS OVERVIEW
FIGURE 65 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 376 CYTOSORBENTS CORPORATION: PRODUCTS & SERVICES OFFERED
13.2 OTHER PLAYERS
13.2.1 MEDICAP CLINIC GMBH
13.2.2 HAIER BIOMEDICAL
13.2.3 BEIJING ZKSK TECHNOLOGY CO., LTD.
13.2.4 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD
13.2.5 PURIBLOOD MEDICAL
*Details on Business overview, Products/Solutions/Services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
